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Introduction
Mutations in the NF1 tumor suppressor gene cause
neurofibromatosis type 1 (NF1), a pandemic autoso-
mal dominant genetic disorder with an incidence of
1:3,500 people (1). Neurofibromin, the protein encod-
ed by NF1, functions as a GTPase-activating protein
(GAP) for Ras by accelerating the hydrolysis of active
Ras-GTP to an inactive Ras-GDP (2, 3). Cutaneous and
plexiform neurofibromas are pathognomonic for NF1
and constitute a major source of morbidity in NF1
patients. Currently, there are no medical treatments to
prevent or diminish neurofibroma growth.
Neurofibromas are characterized by excessive ECM
deposition and close cellular associations among the
multiple cell types within the tumors, including
Schwann cells, fibroblasts, endothelial cells, and mast
cells (4–6). While the pathogenesis of neurofibroma for-
mation is incompletely understood, investigators have
hypothesized that inflammatory mast cells may have a
role in the progression of tumor formation (1) and have
shown that neurofibromas have much higher concen-
trations of mast cells within the tumor as compared
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tiate neurofibroma formation. Neurofibromas occur with high penetrance in mice in which Nf1 is
ablated in Schwann cells in the context of a heterozygous mutant (Nf1+/–) microenvironment. Mast
cells infiltrate neurofibromas, where they secrete proteins that can remodel the ECM and initiate
angiogenesis. Thus, identification of mechanisms responsible for mast cell migration to tumor
microenvironments is important for understanding tumorigenesis and for designing potential ther-
apies. Here, we show that homozygous Nf1 mutant (Nf1–/–) Schwann cells secrete Kit ligand (KitL),
which stimulates mast cell migration, and that Nf1+/– mast cells are hypermotile in response to KitL.
Furthermore, we link hyperactivation of the Ras-class IA-PI3K-Rac2 pathway to increased Nf1+/– mast
cell migration. Thus, these studies identify a novel interaction between Nf1–/– Schwann cells and Nf1+/–
mast cells that is likely to be important in neurofibroma formation.
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with adjacent areas of skin (1, 6, 7). In addition, recent
important insights have been gained by analyzing
genetically engineered mice that develop plexiform neu-
rofibromas (8). In these studies, conditional deletion
of both Nf1 alleles in murine Schwann cells was neces-
sary but not sufficient to generate neurofibromas (8).
When mice harboring a conditional deletion of Nf1 in
Schwann cells were backcrossed onto an Nf1 heterozy-
gous background, however, the animals uniformly devel-
oped neurofibromas that closely resembled human neu-
rofibromas, including dense mast cell infiltrations (8).
These genetic studies demonstrate the essential func-
tion of Nf1 heterozygous cells in neurofibroma forma-
tion and the importance of understanding the basic
mechanisms of how these cells are recruited to and
function within the tumor microenvironment.
Recent studies demonstrate that inflammation is a
critical component of tumor initiation and progression
(reviewed in refs. 9–11). Many cancers arise from sites
of chronic irritation and inflammation (11). It is evi-
dent that the tumor microenvironment and the initia-
tion of angiogenesis, which is largely orchestrated by
inflammatory cells, is an indispensable participant in
the neoplastic process (9, 10). The mechanisms that
control the recruitment of inflammatory cells to tumor
microenvironments, especially in neurofibroma for-
mation, are poorly understood, however.
We have previously shown that Nf1+/– inflammatory
mast cells have increased proliferation and survival in
response to Kit ligand (KitL) both in vitro and in vivo
(12, 13). Furthermore, Nf1+/– mice have increased num-
bers of cutaneous and peritoneal mast cells (12, 13).
Interestingly, mast cells increase dramatically in periph-
eral nerve injury and repair (14), Schwann cell neoplasias
(6), and other cutaneous tumors (15–17). Mast cells can
secrete both nerve growth factor (NGF) (18) and VEGF
(19–21), which are potent stimulants for Schwann cell
proliferation, migration, and survival (21). While these
studies clearly define an interaction between mast cells
and Schwann cells, it remains unclear how mast cells are
recruited to Schwann cells and peripheral nerves.
Given the potential importance of mast cell-Schwann
cell interactions and inflammation within the tumor
microenvironment for neurofibroma formation, we
designed experiments to test whether Nf1–/– Schwann
cells secrete chemotactic factors for mast cell migra-
tion. Furthermore, based on our previous studies, we
tested whether Nf1+/– mast cells were hypersensitive to
chemotactic factors secreted by Nf1–/– Schwann cells.
Here we provide genetic and biochemical evidence
that loss of the Nf1 tumor suppressor gene in Schwann
cells provides a potent chemotactic stimulus for Nf1+/–
mast cells through secretion of soluble KitL and acti-
vation of a specific Ras effector-signaling pathway.
Methods
Animals. Nf1+/– mice were obtained from Tyler Jacks at
the Massachusetts Institute of Technology (Cambridge,
Massachusetts, USA) in a C57BL/6J.129 background
and backcrossed for 13 generations into a C57BL/6J
strain (22). Rac2–/– mice were backcrossed for 12 gener-
ations into a C57BL/6J strain as previously described
(23). The p85α+/– mice were obtained in a C57BL/6J.129
background from Lewis Cantley at Harvard University
(Boston, Massachusetts, USA) and backcrossed for eight
generations into a C57BL/6J strain (24). W41/W41 mice
(W indicates the white-spotted locus) were obtained in
a C57BL/6J background from The Jackson Laboratory
(Bar Harbor, Maine, USA). These studies were conduct-
ed with a protocol approved by the Indiana University
Laboratory Animal Research Center. The Nf1, p85α, and
Rac2 alleles were genotyped by PCR, as previously
described (13, 24). The W41 genotyping was inferred
from the characteristic mottled, white coat color in the
W41/W41 mice and a white abdominal spot in the W41+/–
mice (12). Multiple F0 founders were used to generate
the four F2 Nf1 and Rac2 genotypes used in the experi-
ments as follows: F0: Nf1+/–; Rac2+/+ × Nf1+/+; Rac2–/–. F1:
Nf1+/–; Rac2+/– × Nf1+/+; Rac2+/–. F2: Nf1+/–; Rac2–/– × Nf1+/+;
Rac2–/–, Nf1+/–; Rac2+/+ × Nf1+/+; Rac2+/+. Multiple F0
founders were used to generate mast cells from embry-
onic day 13.5 fetal liver from the four F2 Nf1 and p85α
genotypes as follows: F0: Nf1+/–; p85α+/+ × Nf1+/+; p85α+/–.
F1: Nf1+/–; p85α+/– × Nf1+/+; p85α+/–. F2: Nf1+/–; p85α–/– ×
Nf1+/+; p85α–/–, Nf1+/–; p85α+/+ × Nf1+/+; p85α+/+. Multiple
F0 founders were used to generate the four F2 Nf1 and
W41 genotypes as follows: F0: Nf1+/–; W41+/+ × Nf1+/+;
W41/W41. F1: Nf1+/–; W41+/– × Nf1+/+; W41+/–. F2: Nf1+/–;
W41/W41 × Nf1+/+; W41/W41, Nf1+/–;  W41+/+ × Nf1+/+; W41+/+.
Bone marrow mast cell and fetal liver mast cell cultures. To
generate the four F2 Nf1 and Rac2 experimental geno-
types and the four F2 Nf1 and W41 experimental geno-
types, five bone marrow–derived mast cell (BMMC) lines
from each genotype were generated from 8-week-old
mice. To generate the four F2 Nf1 and p85α experimen-
tal genotypes, embryonic day 13.5 fetal liver–derived
mast cells (FLMCs) were generated exactly as previously
described (13). BMMCs and FLMCs were cultured as
previously described with minor modifications, and the
homogeneity of BMMCs and FLMCs was determined by
Giemsa staining (12). Aliquots of cells were also stained
with Alcian blue and Safranin to confirm that they were
mast cells (25). Furthermore, FACS analysis (Becton
Dickinson Immunocytometry Systems, San Jose, Cali-
fornia, USA) revealed similar forward and side light-scat-
ter characteristics and the same percentage of c-kit+
expression in BMMCs and FLMCs for all murine exper-
imental genotypes (data not shown).
Schwann cell culture and generation of conditional Schwann
cell media. Murine Schwann cells were isolated from WT
Nf1+/– and Nf1–/– mutant mouse embryo dorsal root
ganglia (DRG) at embryonic day 13.5 as described pre-
viously (26). DRGs of the embryos were enzymatically
dissociated, and cells from single embryos were plated
in a single well of a 12-well tissue culture plate in
DMEM (Invitrogen Corp., Grand Island, New York,
USA) containing 10% FBS (HyClone Laboratories,
Logan, Utah, USA) supplemented with 250 ng/ml NGF
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(Harlan Bioproducts for Science Inc., Indianapolis,
Indiana, USA). The medium was changed to serum-free
defined N2 medium (Invitrogen Corp.) containing 250
ng/ml NGF and penicillin/streptomycin (1 mM/ml)
(BioWhittaker Inc., Walkersville, Maryland, USA) on
the next day. After 5–6 days, Schwann cells and neurons
were separated from fibroblasts by lifting up the
Schwann cell-neuron layers from the dish, leaving the
fibroblasts behind. Cells from the same genotype were
pooled, and Schwann cells were enzymatically dissoci-
ated from the neurons in 0.01% collagenase (Sigma-
Aldrich, St. Louis, Missouri, USA). Cells were cen-
trifuged, resuspended in DMEM with 10% FBS, and
plated on poly-L-lysine–coated 100-mm diameter cell
culture plates (Becton Dickinson and Co., Franklin
Lakes, New Jersey, USA) at a density of approximately
106 cells/plate. These cells were considered passage 0.
Cells were changed on the next day to Schwann cell
growth medium containing 10 ng/ml recombinant
human glial growth factor 2 (rhGGF2) (Heregulin;
Sigma-Aldrich), 1 mM/ml penicillin/streptomycin,
with 2 mM forskolin (EMD Biosciences Inc., San
Diego, California, USA) added to suppress fibroblast
growth. After 1 week, cells were trypsinized and replat-
ed at 106 cells/plate (passage 1). Cultures were stained
with an Ab directed against S-100 (Sigma-Aldrich), an
acidic, calcium-binding protein present in Schwann
cells and not fibroblasts, to verify the purity of
Schwann cell populations (Figure 1). In all experi-
ments, cells prepared between passages 1 and 3 were
used. Cells were kept in serum-free N2 medium sup-
plemented with rhGGF2 and forskolin from passage 0
throughout the culture period. Conditioned media
(CM) was harvested as previously described from
Schwann cell cultures on passage 2 after 24 hours of
culture in serum-free DMEM (26). WT, Nf1+/–, and
Nf1–/– Schwann cell viability was greater than 95% by
trypan blue (Sigma-Aldrich) exclusion after culture in
serum-free DMEM (data not shown). The doubling
time for Nf1+/+, Nf1+/–, and Nf1–/– Schwann cells was
approximately 92, 74, and 44 hours, respectively.
Quantification of KitL in conditional Schwann cell media.
Quantitative concentration of murine KitL in Schwann
cell–conditioned media was determined by ELISA
using Quantikine M to measure KitL, according to the
manufacturer’s protocol (R&D Systems Inc., Min-
neapolis, Minnesota, USA). Protein arrays on Schwann
cell–conditioned media were performed with a protein
array assay kit exactly according to the manufacturer’s
protocol (mouse cytokine array kit; Raybiotech Inc.,
Norcross, Georgia, USA).
Ab’s and fluorescence cytometric analysis. Phycoerythrin-
conjugated (PE-conjugated) mAb’s were directed
against c-kit and α5β1. FITC-conjugated Ab’s were
directed against α4β1. All the PE and FITC-conjugated
mAb’s, including isotype control Ab’s, were purchased
from PharMingen (San Diego, California, USA). Mast
cells (106) were incubated at 4°C for 30 minutes with 1
µg of the primary mAb. Cells were washed three times
with PBS containing 0.1% BSA (Sigma-Aldrich) and
analyzed by FACS.
Generation of recombinant retroviral plasmids. Previously
developed recombinant retrovirus constructs were used
in these studies (27). The internal sequences of these
constructs are under the transcriptional control of the
myeloproliferative sarcoma retrovirus promoter. Con-
structs also contain a puromycin resistance gene, pac,
which is under the transcriptional control of the phos-
phoglycerate kinase promoter. Three viruses were used
in these experiments: (a) a virus expressing the full-
length NF1 GTPase-activating related domain (NF1
GRD) and pac (MSCV-NF1 GRD-pac); (b) a virus ex-
pressing a GAP-inactive mutant of the NF1 GRD that
harbors a known human mutation in the arginine fin-
ger loop (R1276P) (28) and pac (MSCV-1276P NF1
GRD-pac), and (c) a virus expressing the selectable
marker gene alone (MSCV-pac) (27).
Retroviral infection of FLMCs. Fetal liver cells were trans-
duced as previously described (27). Briefly, embryonic
day 13.5 fetal liver cells recovered from genotyped liv-
ers were prestimulated for 48 hours in liquid cultures
of RPMI containing 20% FBS supplemented with KitL
(100 ng/ml) (Peprotech Inc., Rocky Hill, New Jersey,
USA) and IL-6 (200 U/ml) (Peprotech Inc.). Cells were
transduced on mitomycin C–treated E86 producer cells
in the presence of KitL, IL-6, and Polybrene (5 µg/ml)
for 48 hours. Transduced cells were then cultured
under conditions to promote mast cell growth as
described previously and as above (27).
Integrin-directed (haptotaxis) migration assays. Integrin-
directed migration (haptotaxis) assays were performed
as previously described (29). Briefly, Falcon cell culture
inserts containing polyethylene terepthalate trat-
etched membranes (Fisher Scientific Co., Pittsburgh,
Pennsylvania, USA) were coated on the underside with
20 µg/ml fibronectin (FN) peptides (Takara Bio Inc.,
Shiga, Japan) for 2 hours at 37°C, rinsed with PBS, and
blocked with 2% BSA for 30 minutes at room tempera-
ture. The transwells were then placed into the lower
chamber containing 500 µl of RPMI medium alone or
in combination with either KitL, WT-conditioned
Schwann cell media, Nf1+/– Schwann cell–conditioned
media, or Nf1–/–-conditioned Schwann cell media. Mast
Figure 1
Isolation of purified populations of Schwann cells from day 13.5
WT and Nf1–/– embryonic DRG. Immunohistochemical staining of
S-100 Schwann cells.
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cells were resuspended at 1 × 105 to 2 × 105 cells in 100
µl of RPMI medium added to the top of each chamber
and allowed to migrate toward the underside of the top
chamber. Following 3 hours of incubation at 37°C in a
5% CO2 incubator, nonmigratory cells on the upper
membrane surface were removed with a cotton swab,
and migrated cells attached to the bottom surface of
the membrane were stained with 0.1% crystal violet in
0.1 M borate, pH 9.0, 2% ethanol for 20 minutes at
room temperature as previously described (29). The
average number of migrated cells per higher-power
field was counted with an inverted microscope using
×20 objective lens. As a control, cell migration on BSA
was also determined and was less than 0.001% of the
total cell population (data not shown).
Motility assay. Mast cell motility was directly observed
by time-lapse imaging of cells exposed to a gradient of
10 ng/ml KitL in a Dunn chemotaxis chamber (Weber
Scientific International Ltd., Surrey, United Kingdom).
Cells (2 × 104 to 5 × 104 in 10 µl RPMI) were applied to
FN fragment H-296–covered (Takara Bio Inc.) glass
coverslips and allowed to adhere for 10 minutes at
37°C. The coverslips were mounted on the Dunn
chamber, the inner well of which was filled with RPMI
and the outer well with RPMI and KitL. The chamber
was sealed and mounted on the stage of a Nikon
Diaphot 300 inverted microscope equipped with dif-
ferential interference contrast optics (Olympus Ameri-
ca Inc., Melville, New York, USA). Chamber tempera-
ture was maintained at 37°C using a stage heater
(Instec Inc., Boulder, Colorado, USA). The chamber was
allowed to equilibrate for 20 minutes to allow a stable
gradient to form. Images were recorded digitally at 15-
second intervals using a ×40 long working distance
objective and a Spot RT-cooled charged coupled device
camera and analyzed using Metamorph software (Uni-
versal Imaging Corp., West Chester, Pennsylvania,
USA). The centroid coordinates of cells at each time
point were determined on calibrated images and used
to calculate the speed and direction of migration.
Filamentous actin quantitation. Filamentous actin (F-actin)
quantitation was performed as previously described
(30). Briefly, fluorescence cytometry was used to
quantitate the amount of F-actin per mast cell. Mast
cells (106) were resuspended in 1 ml of HBSS (Sigma-
Aldrich) in polypropylene tubes (Fisher Scientific Co.,
Hanover Park, Illinois, USA) and warmed at 37°C for 3
minutes prior to addition of KitL or carrier. Cells were
fixed after the specified time by addition of 10 vol of
PBS containing 4.6% formaldehyde and 0.1% BSA.
Fixed cells were treated with 0.01% Triton X-100
(Sigma-Aldrich) in PBS for 5 minutes at 22°C, washed,
and then incubated with 160 nM FITC-phalloidin
(Sigma-Aldrich) for 20 minutes at 22°C prior to FACS
analysis by fluorescence cytometry. A minimum of
10,000 mast cell events was recorded routinely, and the
results are reported as the mean channel fluorescence.
Assays were performed in triplicate.
Results
Nf1–/– Schwann cell–conditioned media is a potent stimulus
for Nf1+/– mast cell migration. The mechanism of Nf1+/–
mast cell recruitment to neurofibromas is not known.
Thus, we tested whether Nf1-deficient Schwann cells
secrete soluble factors to stimulate mast cell migration.
We initially isolated DRG from day 13.5 WT, Nf1+/–,
and Nf1–/– embryos to establish primary murine
Schwann cell cultures. To ensure the purity of these
cultures, cells were stained with an Ab directed against
S-100, an acidic, calcium-binding protein present in
Figure 2
Effect of WT, Nf1+/–, and Nf1–/– Schwann cell CM on WT and Nf1+/– mast cell haptotaxis. (a) Transwells were coated with recombinant FN
and mast cell migration assays were performed in response to WT, Nf1+/–, and Nf1–/– Schwann cell CM. The number of WT and Nf1+/– mast
cells that had migrated to the bottom surface of the FN-coated membrane in response to Schwann cell CM were counted after staining the
cells with crystal violet. A representative photomicrograph of the WT- and Nf1+/–-migrated mast cells, which stain purple, is shown for each
experimental condition. (b) The average numbers of WT and Nf1+/– mast cells per ten high-power fields, which migrated in response to either
105 WT, Nf1+/–, or Nf1–/– Schwann cell CM are shown. Data represent the mean number of migrated cells per ten high-power fields ± SEM
of four independent experiments. *P < 0.05 for Nf1+/– versus WT mast cells in response to either WT Schwann cell CM or Nf1+/– Schwann
cell CM. **P < 0.05 for WT mast cells in response to both WT and Nf1+/– Schwann cell CM versus Nf1–/– Schwann cell CM; ***P < 0.01 for
Nf1+/– mast cells in response to both WT and Nf1+/– versus Nf1–/– Schwann cell CM by the Student’s paired t test. HPF, high-power field.
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Schwann cells, and performed immunohistochemistry.
Greater than 98–100% of the cells in WT, Nf1+/–, and
Nf1–/– cultures were S-100 positive as analyzed by
immunohistochemistry (Figure 1). To further test the
purity of our cultures, we made single-cell suspensions
and stained the cells with a fluorescence-conjugated Ab
directed against S-100 and performed fluorescence
cytometry; 98–100% of the cells in each experimental
group expressed S-100 (data not shown).
After obtaining primary WT, Nf1+/–, and Nf1–/–
Schwann cells, we collected CM from each genotype. To
test whether WT, Nf1+/–, or Nf1–/– CM would stimulate
either WT or Nf1+/– mast cell migration, we coated tran-
swells with recombinant FN and performed migration
assays in response to WT, Nf1+/–, and Nf1–/– CM. After 3
hours of incubation in the transwells, the number of
Nf1+/– and WT mast cells that had migrated to the bot-
tom surface of the FN-coated membrane were counted
after staining the cells with crystal violet. WT and Nf1+/–
mast cells migrated in response to CM from each
Schwann cell genotype (Figure 2, a and b). While the
migration of both mast cell genotypes was augmented in
response to Nf1–/– Schwann cell CM, the tumorigenic cell
in neurofibromas (8), the absolute number of Nf1+/– mast
cells migrating to Nf1–/– Schwann cell–conditioned media
is significantly higher compared with WT mast cells (Fig-
ure 2b). These data demonstrate that: (a) Schwann cells
secrete soluble factor(s) that stimulate mast cell migra-
tion; (b) CM from Nf1–/– Schwann cells has more potent
effects in this assay than WT or Nf1+/– CM; and (c) Nf1+/–
mast cells are specifically more responsive to Nf1–/– CM.
Identification of KitL in Nf1–/– Schwann cell–conditioned
media as a potent stimulus for Nf1+/– mast cell migration. We
performed protein and ELISA assays on WT and Nf1–/–
CM to identify soluble mast cell chemotactic factor(s).
In addition, we performed real-time PCR on mRNA har-
vested from WT or Nf1–/– Schwann cells. These studies
revealed several soluble chemokines and growth factors
previously linked to mast cell migration. Specifical-
ly, VEGF, monocyte chemotactic factor 1 (MCP-1),
RANTES, and KitL were detected in both WT and Nf1–/–
Schwann cell CM, and each soluble protein was found
in greater concentrations in Nf1–/– CM (unpublished
results). We next tested whether various concentrations
of recombinant VEGF, MCP-1, or RANTES, would
stimulate the migration of either WT or Nf1+/– mast
cells by performing migration assays on FN-coated tran-
swells. None of these soluble proteins alone or in com-
bination stimulated either WT or Nf1+/– mast cell migra-
tion over a wide range of concentrations, though they
did modestly enhance migration in the presence of
recombinant KitL (n = 3, and data not shown).
Given this observation and the fact that KitL is known
to be a potent stimulus for mast cell migration both in
vitro and in vivo (13), we tested whether KitL was a
growth factor in WT, Nf1+/–, and Nf1–/– Schwann cell
CM, which promotes mast cell migration. In addition,
we had previously observed that Nf1+/– mast cells had
increased proliferation and survival in response to KitL
(12, 13). We determined the concentration of KitL in
WT, Nf1+/–, and Nf1–/– Schwann cell CM by ELISA.
While KitL was detected in CM from each genotype, the
Figure 3
Quantification of the concentration of KitL in Schwann cell CM and the effect of pharmacologic or genetic inhibition of c-kit activity on mast
cell migration to Schwann cell CM. (a) Concentration of murine KitL in WT, Nf1+/–, and Nf1–/– Schwann cell CM was determined by ELISA.
Results represent the mean ± SEM of five independent collections from five independent Schwann cell cultures. *P < 0.05 for Nf1–/– versus
WT or Nf1–/– versus Nf1+/– by the Student’s paired t test. (b) WT and Nf1+/– mast cells (2 × 105) were preincubated with a neutralizing Ab to
the c-kit RTK, and haptotaxis assays were performed to either WT or Nf1–/– Schwann cell CM. Results represent the mean ± SEM of five inde-
pendent experiments. *P < 0.05 for WT mast cell migration in response to WT or Nf1–/– Schwann cell CM in the presence or absence of the
c-kit–neutralizing Ab. **P < 0.05 for Nf1+/– mast cell migration in response to WT or Nf1–/– Schwann cell CM in the presence or absence of
the c-kit–neutralizing Ab by the Student’s paired t test. (c) Haptotaxis of mast cells of the four Nf1 and W genotypes in response to either
2 × 105 WT or Nf1–/– Schwann cell CM. Results represent the mean ± SEM of five independent experiments. *P < 0.05 for W41/W41 versus
WT mast cell migration in response to either WT or Nf1–/– Schwann cell CM. **P < 0.05 for Nf1+/–; W41/W41 versus Nf1+/– mast cell migra-
tion in response to either WT or Nf1–/– Schwann cell CM by the Student’s paired t test.
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concentration of KitL was approximately sixfold high-
er in Nf1–/– CM compared with WT controls (Figure 3a).
Interestingly, CM from Nf1+/– Schwann cells contained
similar concentrations of KitL compared with WT CM.
We next tested whether pretreatment of WT and Nf1+/–
mast cells with a blocking Ab to c-kit would inhibit
mast cell migration to either WT or Nf1–/– Schwann cell
CM in a migration assay. Preincubating WT and Nf1+/–
mast cells with an anti–c-kit Ab significantly inhibited
the migration of both mast cell genotypes to either WT
or Nf1–/– CM (Figure 3b). Importantly, preincubation of
Nf1+/– mast cells with an anti–c-kit Ab reduced their
migration to WT levels in response to Nf1–/– Schwann cell
CM (Figure 3b). These data suggest that the increased
migration of Nf1+/– mast cells to Nf1–/– Schwann cell CM
is linked, in part, to increased activation of the KitL/
c-kit–signaling pathway.
The W locus encodes the c-kit receptor tyrosine kinase
(RTK). We exploited the W41 strain, which carries a point
mutation that reduces RTK activity approximately 85%
to test the role of c-kit signaling in mast cell migration
in response to Schwann cell CM. W41/W41mice and Nf1+/–
mice were intercrossed to generate mast cells lines from
the four F2 progeny. We reasoned that W41/W41 Nf1+/–
mast cells would have a migration pattern similar to WT
cells in response to the Nf1–/– Schwann cell CM if KitL is
the primary mast cell chemotactic factor responsible for
the increased migration of Nf1+/– mast cells. In multiple
independent migration assays, both W41/W41 and Nf1+/–;
W41/W41 mast cells had decreased migration in response
to WT and Nf1–/– CM compared with WT and Nf1+/–
mast cell controls (Figure 3c). Importantly, Nf1+/–;
W41/W41 mast cell migration was reduced to WT levels in
response to Nf1–/– Schwann cell CM (Figure 3c). Thus,
these experiments identify KitL as a soluble growth fac-
tor in Nf1–/– Schwann cell CM that preferentially
enhances the migration of Nf1+/– mast cells.
Haploinsufficiency of Nf1 increases mast cell migration and
F-actin content in response to recombinant murine KitL. We
have previously shown that Nf1+/– mast cells have
increased proliferation and survival in response to KitL
Figure 4
Effect of heterozygosity of Nf1 on mast cell haptotaxis and F-actin
content in response to rmKitL. (a) Haptotaxis of WT and Nf1+/– mast
cells in response to 10 ng/ml rmKitL. Results represent the mean ±
SEM of five independent experiments. *P < 0.05 for Nf1+/– versus WT
by the Student’s paired t test. (b) Sequential exposures of Nf1+/– and
WT mast cells taken at 2.5-minute intervals during exposure to a 10
ng/ml KitL gradient (from left to right) for 1 hour. Mast cells were
allowed to adhere to FN-coated glass coverslips for 15 minutes before
being loaded into the chemotactic gradient of a Zigmond chamber.
Nf1+/– mast cells demonstrated greatly enhanced movement to the
rmKitL gradient compared with WT cells. (c) Percentage of Nf1+/– or
WT cells moving at various speeds during videomicroscopy. The aver-
age speed of directed movement was calculated from data collected
from the second 30-minute interval of videomicroscopy from WT and
Nf1+/– samples (n >100 cells analyzed per genotype). Histogram
depicts the results from one representative experiment. Two other
experiments showed similar results. (d) F-actin content in BMMCs.
Mast cells were stimulated with 10 ng/ml rmKitL and fixed, at the time
points indicated, by addition of formaldehyde. WT and Nf1+/– cells
were examined in triplicate. Results are expressed as mean channel
fluorescence (MCF) and represent the mean of four independent
experiments per genotype. *P < 0.001 for all comparisons between
genotypes using a Student’s paired t test.
Figure 5
Effect of inhibition of adherence to the α4β1or α5β1 integrins on WT
and Nf1+/– mast cell haptotaxis. WT and Nf1+/– mast cells were prein-
cubated with a neutralizing Ab to the α4β1 or α5β1 integrins, or an
isotype control Ab, and haptotaxis assays were performed to rmKitL.
Results represent the mean ± SEM of five independent experiments
following a 3-hour stimulation to KitL. *P < 0.05 for WT or Nf1+/–
mast cell migration in response to recombinant KitL in presence or
absence of the α4β1-neutralizing Ab or the isotype Ab control using
a Student’s paired t test.
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and have identified distinct Ras effector pathways
responsible for these phenotypes (13). Given that Nf1+/–
mast cells have increased migration to Nf1–/– Schwann
cell CM, which is mediated in part via signaling
through the KitL/c-kit pathway, we wished to identify
the biochemical mechanisms responsible for this Nf1+/–
mast cell phenotype. To confirm that Nf1+/– mast cells
would also demonstrate increased migration in
response to recombinant murine KitL (rmKitL), we
coated transwells with recombinant FN and compared
the migration of WT and Nf1+/– mast cells to rmKitL.
Consistent with increased migration to Schwann cell
CM, Nf1+/– mast cells had a twofold increase in migra-
tion in response to rmKitL compared with WT controls
(Figure 4a). We next compared the migration of Nf1+/–
and WT mast cells on FN-coated surfaces in response
to rmKitL using single-cell video microscopy. Similar
to our results using FN-coated transwells, a greater per-
centage of Nf1+/– mast cells moved at greater speeds
compared with WT controls (Figure 4, b and c).
Polymerization of the actin cytoskeleton drives the
initial extension of the plasma membrane at the cell
front to form small adhesions, which promotes rapid
cell migration (31). Given the increased migration rate
of Nf1+/– mast cells, we compared F-actin content in
Nf1+/– and WT mast cells following stimulation with
rmKitL. Following activation with rmKitL, both mast
cell genotypes were stained with phalloidin to quanti-
tate levels of F-actin by both fluorescence cytometry
and microscopy. In both assays, Nf1+/– mast cells had
increased F-actin content compared with WT cells after
1 minute of stimulation with rmKitL (Figure 4d). Sur-
prisingly, Nf1+/– mast cells had greater F-actin content
at baseline compared with F-actin content obtained in
WT cells stimulated with rmKitL (Figure 4d). Impor-
tantly, in multiple independent experiments (n = 6), the
adhesion of Nf1+/– mast cells to FN at baseline and in
response to rmKitL over varying amounts of time was
not different compared with WT cells (data not
shown). Thus, differences in migration between the
two experimental genotypes cannot be explained by dif-
ferences in adhesion to FN.
Increased migration of Nf1+/– mast cells to rmKitL is medi-
ated by signaling through the α4β1 integrin. We have recent-
ly shown that activation of c-kit by rmKitL cooperates
with the α4β1 integrin to direct the migration of WT
mast cells on FN (29). Furthermore, previous studies,
including analysis of mice deficient in the expression
of the α4β1 integrin, suggest that α4β1 has an essential
role in normal hematopoietic cell development and
recruitment of immune cells to local sites of inflam-
mation (32, 33). To test whether the increased migra-
tion of Nf1+/– mast cells to rmKitL on FN is mediated
specifically by α4β1, we pretreated Nf1+/– and WT mast
cells with blocking Ab’s against α4β1 and α5β1, which
are the two integrins expressed on recombinant FN.
Compared with the isotype control, anti-α4 Ab treat-
ment of both WT and Nf1+/– cells completely inhibited
the migration of both mast cell genotypes (Figure 5).
Importantly, anti-α5β1 treatment of WT and Nf1+/–
mast cells did not inhibit the migration of either mast
Figure 6
Haptotaxis of Nf1+/– mast cells expressing NF1 GRD or R1276P
mutant NF1 GRD. Nf1+/– mast cells were transduced with the control
retrovirus (pac), NF1 GRD virus, or R1276P NF1 GRD virus, and hap-
totaxis assays were performed in response to rmKitL. Results repre-
sent the mean ± SEM of three independent experiments. *P < 0.05
for comparison of Nf1+/– pac and Nf1+/– R1276P NF1 GRD to WT pac
using a Student’s paired t test.
Figure 7
Effect of Rac2 or p85α deficiency on the haptotaxis of Nf1+/– and
WT mast cells. (a) Haptotaxis of mast cells of the four Nf1 and
p85α genotypes in response to rmKitL. *P < 0.01 for WT versus
Nf1+/–. **P < 0.01 for WT versus p85α–/–. ***P < 0.01 for Nf1+/–
versus Nf1+/–; p85α–/– by the Student’s paired t test. (b) Haptotaxis
of mast cells of the four Nf1 and Rac2 genotypes in response to
rmKitL. *P < 0.01 for WT versus Nf1+/–.; Nf1+/+. **P < 0.01 for
Nf1+/–-; Nf1+/+ versus Nf1+/–; Rac2–/–. ***P < 0.01 for WT versus
Rac2–/– by the Student’s paired t test.
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cell genotype on FN in response to rmKitL (Figure 5).
To ensure that differences between Nf1+/– and WT mast
cell migration were not secondary to different expres-
sion of either α4β1 or α5β1, we compared the surface
expression of these two integrins on WT and Nf1+/–
mast cells. No difference in the surface expression of
either α4β1 or α5β1 was observed between the two mast
cell genotypes (data not shown). Importantly, we did
not detect any differences between the adhesion of
Nf1+/– or WT mast cells to either α4β1 (H296) or α5β1
(CH296) to account for differences in migration (data
not shown). Thus, the increased migration of Nf1+/–
and WT mast cells on FN in response to rmKitL is
specifically mediated by α4β1.
Expression of the NF1 GRD in Nf1+/– mast cells restores
migration to WT levels. Previous studies using non-
hematopoietic cells transduced with either dominant
negative or constitutively active Ras isoforms have
yielded conflicting results about the role of Ras acti-
vation in regulating cellular migration (34–40). We
found that Nf1+/– mast cells stimulated with rmKitL
have increased Ras activity as compared with WT cells
(13). While the GRD of neurofibromin binds Ras with
high affinity and induces a 105-fold increase in the
rate of GTP hydrolysis (41), it is possible that actin-
mediated cytoskeletal functions such as migration
may be altered in Nf1-deficient cells secondary to the
loss of non-GRD functions of neurofibromin. To
determine whether the increased migration of Nf1+/–
mast cells is directly linked to increased Ras activa-
tion, we transduced Nf1+/– and WT mast cells with
either a retrovirus encoding NF1 GRD (MSCV-NF1
GRD-pac) or a control retrovirus (MSCV-pac) and
performed migration assays on FN-coated transwells
in response to recombinant KitL. As previously shown
in primary mast cells (27), we confirmed recombinant
GRD peptide expression in mast cells by immuno-
blotting using a KT3 epitope tag incorporated into
the GRD peptide (data not shown) (27). In addition,
we have shown previously that immunoprecipitated
GRD peptides in transduced mast cells have GAP
activity by stimulating phosphate release from GTP-
loaded Ras (27). Interestingly, expressing the NF1
GRD in Nf1+/– mast cells restored migration to normal
(Figure 6). Given the specificity of the NF1 GRD in
correcting the migration phenotype of Nf1+/– mast
cells, we further tested whether this was due to a
direct effect on Ras. We used a previously generated
GAP-inactive mutant of NF1 GRD that harbors a
mutation in the arginine finger loop (R1276P) (28).
This mutation, which was identified in a family with
a typical NF1 disease, greatly reduces neurofibromin
GAP activity, and we have previously shown that the
R1276P mutant recombinant protein has no catalyt-
ic activity in a GAP assay in mast cells. Expressing the
R1276 mutant protein in Nf1+/– mast cells had no
effect on migration (Figure 6). Collectively, these data
directly link hyperactivation of Ras in Nf1+/– mast cells
to increased migration on FN in response to rmKitL.
Increased migration of Nf1+/– mast cells is mediated by sig-
naling through the class IA PI3K-Rac2 pathway. Given that
elevated Ras activity is responsible for the increased
migration of Nf1+/– mast cells, we next performed exper-
iments to identify Ras effector-signaling pathways
responsible for the Nf1+/– migration phenotype. We
have recently shown that activation of class IA PI3K and
the hematopoietic-specific Rho GTPase, Rac2, is essen-
tial for α4 integrin–directed migration of WT mast cells
in response to rmKitL (29). We have also identified
class IA PI3K and Rac2 as specific downstream Ras
effectors that are hyperactivated in Nf1+/– mast cells in
response to rmKitL stimulation (13). Given these pre-
vious observations, we used cells from compound
mutant mice to test whether increased activation of the
class IA PI3K-Rac2 pathway was directly linked to the
Nf1+/– mast cell migration phenotype.
Nf1+/– mice were intercrossed with p85α+/– mice to
generate Nf1+/–; p85α–/– and p85α–/– FLMCS along with
appropriate experimental controls. In previous studies,
we have shown no differences in the functional
responses of FLMCs compared with BMMCs (13).
p85α is a regulatory subunit of class IA PI3K, and other
studies have shown that p85α–/– mast cells have a
greater that 90% reduction in class IA PI3K activity fol-
lowing stimulation with rmKitL (42). After establish-
ing FLMCs for each experimental group, migration
assays were performed on FN-coated transwells. Con-
sistent with our previous studies, the migration of
p85α−/− mast cells was greatly diminished in response
to rmKitL compared with WT mast cells (Figure 7a).
The migration of Nf1+/–; p85α–/– mast cells, however,
was also greatly reduced compared with both WT and
Nf1+/– mast cells (Figure 7a). Thus, while Ras activates
multiple downstream signaling pathways in mast cells,
Ras activation of class IA PI3K is essential for the migra-
tion of Nf1+/– mast cells on FN in response to rmKitL.
Our previous studies show the Rac2 activity is
decreased in p85α –/– mast cells after stimulation with
rmKitL, which genetically positions Rac2 downstream
of class IA PI3K in mast cells (29). Furthermore, we
have previously shown that Rac2 is hyperactivated in
Nf1+/– mast cells in response to rmKitL and Ras-Rac2
activation is directly responsible for the increased pro-
liferation of Nf1+/– mast cells (13). Rac2–/– mice have
multiple mast cell defects, including impairment of
actin-mediated cytoskeletal cell functions (43). Given
these previous observations and the importance of
Rac2 activation in mast cell migration, we intercrossed
Rac2–/– and Nf1+/– mice, established mast cells from the
four F2 progeny, and performed migration assays on
FN-coated transwells. Consistent with previous stud-
ies, Rac2–/– mast cells had diminished migration on FN
in response to rmKitL compared with controls (Figure
7b). Nf1+/–; Rac2–/– mast cells had a 40–50 % reduction
in migration compared with Nf1+/– mast cells in
response to rmKitL (Figure 7b), however. Importantly,
the migration of Nf1+/–; Rac2–/– mast cells was similar
to WT cells in multiple independent experiments (n = 6;
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Figure 7b). Thus, these experiments provide direct
genetic evidence that the increased migration of Nf1+/–
mast cells is mediated through increased activation of
the specific Rac2 isoform.
Discussion
Recent genetic studies show that Nf1–/– Schwann cells
are necessary but not sufficient for neurofibroma for-
mation and demonstrate that other Nf1+/– cells within
neurofibromas are essential for tumor formation (8).
Specifically, when Zhu and colleagues used a Krox 20
Cre promoter to induce somatic inactivation of Nf1 in
Schwann cells only, mice did not develop neurofibro-
mas. When these mice were backcrossed onto an Nf1+/–
background such that all non-Schwann cell lineages
were haploinsufficient at Nf1, however, the mice uni-
formly developed plexiform neurofibromas. These
genetic experiments provide direct evidence that hap-
loinsufficiency of Nf1 in non-Schwann cell lineages is
required for tumor formation.
Given that mast cells increase in neurofibromas (1,
6, 7, 14) and secrete proteins within tumor microen-
vironments to remodel ECM and to initiate neoan-
giogenesis (9, 10, 15), we hypothesized that Nf1–/–
Schwann cells secrete soluble factors to activate specif-
ic signaling pathways within Nf1+/– mast cells to pro-
mote their migration to Nf1–/– Schwann cells. Nf1+/–
mast cells, in turn, may secrete soluble factors into the
tumor microenvironment. A basic tenet in mast cell
biology is that bone marrow–derived mast cell progen-
itors circulate in the peripheral blood and migrate by
transmigration through endothelial cells into tissues
where they undergo final maturation under the influ-
ence of local microenvironmental factors. Adhesion
and integrin-directed migration (termed haptotaxis) in
part regulates the accumulation of mast cells into tis-
sues (44). While our previous studies show that Nf1+/–
mast cell progenitors have increased survival and pro-
liferation in response to recombinant KitL (12, 13), one
potential explanation for the accumulation of mast
cells in neurofibromas is that haploinsufficiency of Nf1
alters mast cell haptotaxis toward growth factors
secreted by Nf1–/– Schwann cells.
In these experiments we demonstrate that Nf1–/–
Schwann cells secrete various proteins that have been
previously linked to the recruitment of inflammatory
cells to tumor microenvironments. Despite the diversi-
ty of proteins secreted by Nf1–/– Schwann cells, we pro-
vide several lines of evidence to demonstrate that KitL
is a major growth factor that promotes the migration
of Nf1+/– mast cells. These in vitro studies are intriguing
given that previous analysis in human neurofibromas
reveals markedly increased amounts of KitL transcripts
(6, 14) and that transformed human Schwann cell lines
secrete high concentrations of KitL (6, 45). While other
cell types, such as fibroblasts and endothelial cells may
also secrete KitL, our studies clearly demonstrate that
the initiating tumorigenic cell within neurofibromas
secretes at least fivefold to sixfold higher concentra-
tions of KitL as compared with Nf1+/– and WT Schwann
cells. It is intriguing that nullizgous loss of Nf1 may
result in an increased secretion of growth factors
important in tumorigenesis in a range of malignancies.
Recently, Donovan and colleagues demonstrated that
Nf1–/– myb immortalized myeloid cells secrete high
concentrations of GM-CSF (46), a growth factor previ-
ously established to be critical to the progression of
tumorigenesis in juvenile myelomonocytic leukemia
(47). Thus, previous studies and the current data sug-
gest a paradigm where loss of Nf1 results in an increase
in growth factor production that initiates an autocrine
or paracrine loop important for the progression of
tumorigenesis. The detailed mechanisms underlying
this increased secretion of cytokines in Nf1 nullizygous
Schwann cells is currently being investigated.
Having identified KitL as the chemotactic stimulus
secreted by Nf1–/– Schwann cells, we next designed exper-
iments to identify the biochemical mechanisms respon-
sible for the increased migration of Nf1+/– mast cells.
Recent studies show that hematopoietic cell attachment
to α4β1 and α5β1 is critical for migration in response
to KitL, and mast cells express both integrins (29).
Though neurofibromas were initially described as
“white tumors,” they have been found to be highly vascu-
lar (48). Importantly, endothelial cells express VCAM-1,
which is the receptor for α4β1, and human and murine
mast cells readily attach to endothelial cells through
VCAM-1 (49). The α4β1–VCAM-1 interactions are espe-
cially important since mast cells are thought to migrate
to areas of inflammation by attachment and transmi-
gration through endothelial cells (50, 51). In our studies,
we provide experimental evidence to show that heterozy-
gous inactivation of Nf1 promotes rapid mast cell hapto-
taxis specifically on α4β1 integrins in response to KitL.
The observation that Nf1+/– mast cells have
increased migration on α4β1 integrins is interesting
since other studies testing the effect of increased Ras
activation on cellular migration and adhesion have
yielded conflicting results (34–40). Specifically, im-
mortalized cell lines transfected with constitutively
activated Ras proteins have been shown to have either
increased or decreased migration. Given these previ-
ous reports, it was unclear whether the increased
migration of Nf1+/– mast cells was linked to increased
Ras activity in response to KitL. The NF1 gene is a
large, complex gene with 60 exons. The only ascribed
function of the NF1 gene in mammalian cells is to
function as a GAP for Ras, however, and this function
is specifically mediated through the GRD of the NF1
gene (41). Furthermore, we have previously shown
previously that reintroduction of the GRD with
recombinant retroviruses into Nf1–/– hematopoietic
progenitors diminishes their proliferative responses
via decreased Ras activity (27). Similar to our previ-
ous studies (52), we found that reintroduction of the
GRD into Nf1+/– mast cells reduces their migration
on FN to WT levels in response to KitL. Similar
results were also obtained when Nf1–/– Schwann cell
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CM was used as a stimulus (unpublished results). In
addition, we also show that introduction of a GRD
harboring a known patient mutation that disables
Ras GTPase activity does not alter the migration of
Nf1+/– mast cells. These data provide direct evidence
that the Nf1+/– motility phenotype is secondary to
increased Ras activity.
An important priority in studying Nf1-deficient cells is
the identification of specific Ras effector pathways, which
are responsible for functional defects. While we have pre-
viously shown that multiple Ras effector pathways are
altered in Nf1+/– mast cells in response to KitL, we provide
genetic evidence that activation of the class 1A-PI3K-Rac2
pathway is directly responsible for the increased migra-
tion of Nf1+/– mast cells. This is an important observation
since we have previously shown that increased activation
of this signaling pathway is also responsible for the
increased proliferation and survival of Nf1+/– mast cells
(13). Thus, the recruitment and expansion of mast cell
numbers within neurofibromas may be mediated
through a common series of Ras effector targets.
A major effort in our lab and others is now focused on
formally testing the specific contribution of each Nf1+/–
cell lineage identified within the tumor microenviron-
ment to neurofibroma formation. It is possible that
other cells within the tumor microenvironment (partic-
ularly endothelial cells and fibroblasts), through para-
crine interactions with mast cells and/ or Schwann cells,
may contribute to the tumor progression of neurofibro-
mas. Understanding the complex interaction between
these cell types within the tumor is an important com-
ponent of these studies. In addition, the tumors that
have been observed in the murine model to date have
been plexiform neurofibromas derived from DRG and
cranial nerves. Whether this is a consequence of the
expression pattern of the Cre transgene used in those
experiments or alternatively reflects a slightly different
pathogenesis from the benign cutaneous neurofibromas
remains an important question. It is reasonable to spec-
ulate based on the existing evidence linking inflamma-
tion to tumorigenesis that reduction of mast cell infil-
tration into neurofibromas may result in decreased
growth or occurrence. If this is the case, our studies pro-
vide several attractive therapeutic targets including inhi-
bition of c-kit activity and adhesion to α4β1. Imatinib
mesylate is currently being used to treat patients with
chronic myelogenous leukemia and gastrointestinal
tumors where c-kit activation is central to the disease
pathogenesis (52). Furthermore, drugs targeting α4β1
activation are currently being tested in clinical trials to
treat multiple sclerosis and Crohn disease where inflam-
matory cell recruitment to both the CNS and gastroin-
testinal tract by adhesion to α4β1 is thought to be impor-
tant for disease progression (53–55). Based on our work,
these treatments may be potentially useful in treating or
preventing neurofibroma formation in NF1 patients. In
addition, pharmacologic inhibition of PI3K or the
hematopoietic-specific small Rho GTPase, Rac2, may
decrease mast cell numbers within neurofibromas.
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